Joel P. Berger
Department of Molecular Endocrinology
Merck Research Laboratories
Rahway
New Jersey 07065
USA
Name/email consistency: high
- PPARs: therapeutic targets for metabolic disease. Berger, J.P., Akiyama, T.E., Meinke, P.T. Trends Pharmacol. Sci. (2005)
- Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Berger, J.P., Petro, A.E., Macnaul, K.L., Kelly, L.J., Zhang, B.B., Richards, K., Elbrecht, A., Johnson, B.A., Zhou, G., Doebber, T.W., Biswas, C., Parikh, M., Sharma, N., Tanen, M.R., Thompson, G.M., Ventre, J., Adams, A.D., Mosley, R., Surwit, R.S., Moller, D.E. Mol. Endocrinol. (2003)
- The mechanisms of action of PPARs. Berger, J., Moller, D.E. Annu. Rev. Med. (2002)
- Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Berger, J., Wagner, J.A. Diabetes Technol. Ther. (2002)
- Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity. Berger, J., Tanen, M., Elbrecht, A., Hermanowski-Vosatka, A., Moller, D.E., Wright, S.D., Thieringer, R. J. Biol. Chem. (2001)
- A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. Berger, J., Patel, H.V., Woods, J., Hayes, N.S., Parent, S.A., Clemas, J., Leibowitz, M.D., Elbrecht, A., Rachubinski, R.A., Capone, J.P., Moller, D.E. Mol. Cell. Endocrinol. (2000)
- Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. Berger, J., Leibowitz, M.D., Doebber, T.W., Elbrecht, A., Zhang, B., Zhou, G., Biswas, C., Cullinan, C.A., Hayes, N.S., Li, Y., Tanen, M., Ventre, J., Wu, M.S., Berger, G.D., Mosley, R., Marquis, R., Santini, C., Sahoo, S.P., Tolman, R.L., Smith, R.G., Moller, D.E. J. Biol. Chem. (1999)
- A high-capacity assay for activators of glucose incorporation into glycogen in L6 muscle cells. Berger, J., Hayes, N.S. Anal. Biochem. (1998)
- Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Berger, J., Bailey, P., Biswas, C., Cullinan, C.A., Doebber, T.W., Hayes, N.S., Saperstein, R., Smith, R.G., Leibowitz, M.D. Endocrinology (1996)
